Your current location:HomeNewsNews

Academician Leading | Multi-Center Clinical Research Symposium Was Successfully Hold.

On February 23, it was initiated by Wuhan Emerson Life Technology Co., Ltd., led by the First Affiliated Hospital of Naval Military Medical University (Shanghai Changhai Hospital), and seven domestic top tertiary hospitals jointly participated in the clinical trials of blood methylation projects for colorectal cancer and esophageal cancer. The program discussion meeting was officially held in Shanghai Changhai Hospital.

This project is led by Academician Li Zhaoshen, Academician of Chinese Engineering, Director of Gastroenterology Department of Shanghai Changhai Hospital, Director of National Gastrointestinal Clinical Research Center, and Director of National Center for Quality Control of Digestive Endoscopy. The meeting was chaired by Professor Bo Yu of Shanghai Changhai Hospital, and more than 20 authoritative experts in the digestive field, including Professor Wang Luowei and Professor Du Yiqi of Shanghai Changhai Hospital, as well as several well-known deans and directors, participated.

Intestinal cancer and esophageal cancer are common malignant tumors of the digestive tract in China. Experts in the field of digestion represented by Academician Li Zhaoshen of Shanghai Changhai Hospital have been committed to promoting the early diagnosis and early treatment of digestive tract tumors, but the non-invasive diagnosis of early digestive tract cancer is still a A difficult clinical problem. This seminar on the colorectal cancer blood methylation detection project and the esophageal cancer blood methylation detection project of Emerson Life Technology will fill in the blank of non-invasive screening technology for early gastrointestinal cancer, and promote the non-invasive detection of early gastrointestinal cancer. The scientifically rigorous demonstration of new screening technologies lays an important foundation.

Academician Li Zhaoshen delivered a speech at this multi-center research seminar. Academician Li said: Wuhan Emerson has developed a blood methylation detection product for colorectal cancer and esophageal cancer. Among them, esophageal cancer blood methylation is the first to use methylation methods. Products for esophageal cancer detection, thank you very much for participating in this meeting during your busy schedule, and wish our meeting a complete success!

Zhang Lianglu, chairman of Emerson Life Technology, introduced the company's situation to the experts. Zhang Lianglu said: Since 2015, Emerson Life Technology has been focusing on the research and development of early diagnosis and early screening products for high-incidence malignant tumors. With the product concept of 'convenience', Amisen Life Technology has established a complete technology platform for early screening and diagnosis of tumors, and has developed nearly 10 products based on the methylation technology platform. Previously, the colorectal cancer fecal DNA detection product developed by the company, Aichangkang®, was recognized by the Ministry of Industry and Information Technology's scientific and technological achievements evaluation as: the overall technology has reached the international advanced level (click for details). Aichangkang® has four advantages: more comprehensive, more sensitive, faster and more convenient, and has excellent clinical performance: sensitivity of 95.3% and specificity of 94.7%. This blood colorectal cancer and blood esophageal cancer detection projects all use the gene methylation and hypersensitive methylation detection technology for Chinese characteristics to develop products, and the colorectal cancer blood methylation detection products are benchmarked The product of American Freenome Company, blood esophageal cancer will effectively fill the gap in the international detection of esophageal cancer, especially esophageal squamous cell carcinoma. Emerson hopes to develop more products for early diagnosis and early screening of tumors that adapt to China's national conditions, and provide more Chinese diagnosis and treatment solutions to the world.

Professor Wang Luowei and Professor Bo Yu respectively introduced the clinical research plan of blood methylation detection for esophageal cancer and bowel cancer to the experts. , and put forward many constructive suggestions on the intake and discharge standards, quality control, implementation details, etc. In addition, the experts expanded their ideas and ideas for conducting more clinically valuable research. These suggestions not only laid a solid foundation for the smooth implementation of the current project, but also pointed out a clear direction for the expansion of subsequent new projects.

Finally, Academician Li Zhaoshen made a summary and gave further guidance for this program discussion meeting. Academician Li Zhaoshen said: This program discussion meeting is very efficient and rich in content. Experts have put forward a lot of valuable suggestions for the specific implementation of the project plan. It is believed that with the joint efforts of everyone, the two multi-center studies will definitely obtain high-quality results.

It is believed that with the support and guidance of experts and various clinical centers, Amisen Life Technology will continue to work hard in the field of early screening and diagnosis of digestive system cancer, and work with experts to promote the implementation of the project of early screening and early diagnosis of digestive tract cancer. In order to realize the beautiful vision of 'discovering a case of early cancer, saving a life, and a happy family', we will continue to make contributions!

Early tumor screening to defeat cancer

Emerson Life Technology, keep moving forward!

About Emerson Life Technology

Emerson Life Technology focuses on the early detection of high-incidence malignant tumors, providing digestive system tumors (intestinal cancer, gastric cancer, liver cancer, esophageal cancer, pancreatic cancer), gynecological tumors (cervical cancer, endometrial cancer), urinary system tumors (bladder cancer) , Pan-cancer species and other high-incidence malignant tumor genes early detection services.


Related suggestion